The report was based on Google search patterns in 2024 and has identified five key shifts shaping the health and wellness ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

Obesity medicine specialist Sue Pedersen says the updates also focus on individualizing care and move away from relying on ...

Orforglipron led to 11.5% placebo-adjusted weight loss at 72 weeks (among those who adhered to high-dose treatment) in Attain-1, versus 13.9% at 64 weeks in Oasis 4 for the 25-mg dose of oral ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

The week-ending August 8 saw 20 companies in the healthcare sector report their quarterly earnings. With the earnings season ...

If the plan pans out, it would be an enormous boon to Eli Lilly and Novo Nordisk. Currently, many health insurance plans, as ...

Eli Lilly's pill, orforglipron, is a step closer to becoming the first needle-free alternative in the booming market for weight loss drugs.